+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bronchopulmonary Dysplasia - Pipeline Review, H2 2019

  • ID: 4866590
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 68 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Advent Therapeutics Inc
  • Ayuvis Research Inc
  • Ethypharm SA
  • MediPost Co Ltd
  • Orphanix GmbH
  • Syntrix Biosystems Inc
  • MORE
Bronchopulmonary Dysplasia - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H2 2019, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection, premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics and antibiotics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 10 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Advent Therapeutics Inc
  • Ayuvis Research Inc
  • Ethypharm SA
  • MediPost Co Ltd
  • Orphanix GmbH
  • Syntrix Biosystems Inc
  • MORE
Introduction
Report Coverage
Bronchopulmonary Dysplasia - Overview
Bronchopulmonary Dysplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bronchopulmonary Dysplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
Advent Therapeutics Inc
Airway Therapeutics LLC
Ayuvis Research Inc
Chiesi Farmaceutici SpA
Ethypharm SA
Insmed Inc
MediPost Co Ltd
Meridigen Biotech Co Ltd
Orphanix GmbH
Radikal Therapeutics Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Co Ltd
The Cell Factory BVBA
Therabron Therapeutics Inc
Trimunocor Ltd
United Therapeutics Corp
Bronchopulmonary Dysplasia - Drug Profiles
AT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
caffeine citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFMEV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
perfluorooctyl bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pioglitazone + B-YL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pneumostem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Replace Surfactant Protein D for Bronchopulmonary Dysplasia and Lung Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR-4 for Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMC-11901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UNEX-42 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchopulmonary Dysplasia - Dormant Projects
Bronchopulmonary Dysplasia - Discontinued Products
Bronchopulmonary Dysplasia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Bronchopulmonary Dysplasia, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Bronchopulmonary Dysplasia - Pipeline by Advent Therapeutics Inc, H2 2019
Table 12: Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H2 2019
Table 13: Bronchopulmonary Dysplasia - Pipeline by Ayuvis Research Inc, H2 2019
Table 14: Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H2 2019
Table 15: Bronchopulmonary Dysplasia - Pipeline by Ethypharm SA, H2 2019
Table 16: Bronchopulmonary Dysplasia - Pipeline by Insmed Inc, H2 2019
Table 17: Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, H2 2019
Table 18: Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, H2 2019
Table 19: Bronchopulmonary Dysplasia - Pipeline by Orphanix GmbH, H2 2019
Table 20: Bronchopulmonary Dysplasia - Pipeline by Radikal Therapeutics Inc, H2 2019
Table 21: Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, H2 2019
Table 22: Bronchopulmonary Dysplasia - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Table 23: Bronchopulmonary Dysplasia - Pipeline by The Cell Factory BVBA, H2 2019
Table 24: Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics Inc, H2 2019
Table 25: Bronchopulmonary Dysplasia - Pipeline by Trimunocor Ltd, H2 2019
Table 26: Bronchopulmonary Dysplasia - Pipeline by United Therapeutics Corp, H2 2019
Table 27: Bronchopulmonary Dysplasia - Dormant Projects, H2 2019
Table 28: Bronchopulmonary Dysplasia - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Bronchopulmonary Dysplasia, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Advent Therapeutics Inc
  • Airway Therapeutics LLC
  • Ayuvis Research Inc
  • Chiesi Farmaceutici SpA
  • Ethypharm SA
  • Insmed Inc
  • MediPost Co Ltd
  • Meridigen Biotech Co Ltd
  • Orphanix GmbH
  • Radikal Therapeutics Inc
  • Syntrix Biosystems Inc
  • Takeda Pharmaceutical Co Ltd
  • The Cell Factory BVBA
  • Therabron Therapeutics Inc
  • Trimunocor Ltd
  • United Therapeutics Corp
Note: Product cover images may vary from those shown
Adroll
adroll